Catalent expands Chinese presence with two joint ventures

Catalent Pharma Solutions is betting big on the Chinese market, launching two joint ventures for its Softgel Technologies and Clinical Supply Solutions businesses. In the first, it will acquire a majority stake in Zhejiang Jiang Yuan Tang Biotechnology, which produces softgels, and in the second, it will partner with ShangPharma to provide clinical trial supplies in China. Catalent isn't disclosing financial details in either deal. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.